This approval broadens the scope of the MACI® (autologous cultured chondrocytes on porcine collagen membrane) label.

Alnylam announced on June 14, 2022, that its siRNA drug Amvuttra® (vutrisiran) was approved by the FDA for the treatment of polyneuropathy with hereditary transthyretin-mediated amyloidosis (hATTR) in adults.

Roche has announced that the European Commission has granted approval for PiaSky® (crovalimab), an innovative recycling monoclonal antibody that targets the complement protein C5.

Aug 29th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

BioArctic AB revealed the publication of the findings from two phase-1 trials involving exidavnemab(ABBV-0805) in The Journal of Clinical Pharmacology.

This article will use Pfizer as an example to teach you how to quickly learn to read Pharma/Biotech financial reports.

Aug 28th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

SIFI revealed that the European Commission has granted approval for AKANTIOR® (polihexanide) for managing acanthamoeba keratitis (AK) in both adults and children aged 12 and over.

Aug 27th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The European Commission grants approval to Celltrion’s SteQeyma® (CT-P43), a biosimilar version of Stelara® (ustekinumab), for treating several chronic inflammatory disorders.

Galapagos reveals FDA approval of its IND application for the Phase 1/2 ATALANTA-1 trial of CD19 CAR-T therapy, GLPG5101, in non-Hodgkin lymphoma that has relapsed or is refractory.

Moderna, Inc. (NASDAQ:MRNA) reported that the European Commission (EC) has approved mRESVIA® (mRNA-1345), an mRNA vaccine targeting respiratory syncytial virus (RSV), for marketing.